Plan S- a debated initiative to make all government-funded research to open access publishing- has been delayed from January 2020, by a year. COAlition S – the group of funders behind Plan S-has released updated guidelines which state that formal starting point of it mandates will now be January 2021. The revised guidelines were termed with the aim to give publishers additional time to adjust to the required changes and shift their business models. However, some researchers still argue that the delay does not give adequate time for the scientific community to adapt to the changes the bold plan requires.
Reference Link: https://www.nature.com/articles/d41586-019-01717-2
Elsevier has approved its first “read-and-publish” contract with a national consortium of universities and research institutions in Norway. The Norwegian consortium has employed an agreement that rolls the two costs into one, apart from paying distinctly to avail content behind paywalls and make the particular articles instantly available to the scientific community. This is a big deal because there are many librarians and speakers who trust this model will decrease subscription charges while improving open-access publications.
Reference Link: https://www.insidehighered.com/news/2019/04/24/elsevier-agrees-first-read-and-publish-deal
The New England Journal of Medicine or NEJM thinks open-access is not a good idea. An editorial published by Charlotte Haug, one of the correspondents of NEJM reports that the “experiment” has failed, and free access to scientific publications hasn’t delivered on its promises. NEJM is particularly concerned about “Plan S”, a plan in Europe that suggests that all scientists whose work is funded by the community be required to publish their results in open-access venues. Plan S is due to take upshot in 2020.
Reference Link: https://www.forbes.com/sites/stevensalzberg/2019/04/01/nejm-says-open-access-publishing-has-failed-right/#59541d546a44
Future Drug Discovery is a peer-reviewed, open access journal covering the latest breakthrough science in drug discovery, research & development. Future Drug Discovery aims to harness high failure rates, presenting new advances and discussing their applications and translation in an openly accessible format, and providing a forum for discussing the field at large. It will be a quarterly publication publishing case histories, methodologies, original research, reviews and opinion articles covering the entire drug discovery pipeline, plus topics of interest to the drug discovery community. A comprehensive list of topics can be found at the journal webpage.
Reference Link: https://www.eurekalert.org/pub_releases/2019-03/fsg-fsg032619.php
According to a study, scientists from pharmaceutical trade publish a higher fraction of their papers open access than academics who aren’t in industry. The open-access papers published by 23 large drug companies, such as Pfizer and Roche has overtaken the quantity of liberally available papers published most prominently in medicine-related fields.“It seems like big pharma has a notable niche in open access,” says Kyle Siler, a social scientist at Utrecht University in the Netherlands.
As a leader in the universal movement toward open access to publicly funded research, the University of California terminated its further subscriptions with Elsevier, the world’s largest scientific publisher. Despite months of bond negotiations, Elsevier was reluctant to meet UC’s key goal: acquiring universal open access to UC research to enable users to view it excluding any charges- as well as to restrain the rising costs associated with for-profit journals. Under Elsevier’s new proposed terms, the publisher would have charged UC authors large publication fees on top of the university’s multi-million dollar subscription, subsequently increasing the cost to the University and greater profits for Elsevier.
Reference link: https://news.berkeley.edu/2019/02/28/why-uc-split-with-publishing-giant-elsevier/
The entire board of the Elsevier-owned Journal of Informetrics surrendered on Thursday to protest over high open-access fees, confining access to data and information commercial control of academic work.
Today, a similar group is launching a new fully open-access journal called Quantitative Science Studies. The journal will be for and by the academic community and will be owned by the International Society for Scientometrics and Informetrics (ISSI). It will be distributed mutually with MIT Press.
The conflict between Elsevier, the world’s biggest publisher of scientific journals, and Germany’s entire university system has dragged on since 2015. However, recently Elsevier has approved continuous access to its paywalled journals for researchers at around 200 German universities and other research institutes that had refused earlier to renew their individual subscriptions. The nationwide deal sought by scientists includes an open-access option, under which all corresponding authors affiliated with German institutions would be allowed to make their papers open to read and share by anyone in the world. This would be a signpost for global efforts to make the results of publicly funded research immediately and freely available to scientists.
Cambridge University Press has reached a major Open Access contract with higher education and research institutions in Sweden. The three-year ‘read and publish’ deal has agreed with Bibsam – an association of 85 higher education and research institutions, led by the National Library of Sweden. It indicates that the authors from institutions affiliated to Bibsam can publish their publicly-financed research articles in the Press’s hybrid and fully Open Access journals. It also gives Bibsam members full access to the Press’ full collection of nearly 400 journals from 1 January 2019.
With Open Access turning into the shared vision of various governments worldwide and a specific concentration inside some European research funders, this extended joint effort permits both Wiley and Hindawi to help the continuous improvement of top-notch open access titles and giving creators extra choices for where and how to publish. This collaboration is an extraordinary case of how Open Access is an intense and powerful driving force of the Open Science landscape, supporting an open and energizing worldwide space of sharing and associating the effect of research for the future generations.
Reference link: http://www.stm-publishing.com/wiley-and-hindawi-expand-open-access-publishing-collaboration/